SpectraScience, Inc. (SCIE-OTC)

SpectraScience, Inc. (“SpectraScience” or “the Company”) is commercializing advanced, minimally invasive diagnostic products using light-based technologies that improve a physician’s ability to diagnose cancer while lowering the cost of diagnosis. The Company’s lead platform—the WavSTAT® Optical Biopsy System—is in the final stages of a multicenter, 1,200-patient European study and is poised to commence sales in Europe and potentially Saudi Arabia in 2016. The current WavSTAT4 product is initially targeted to the colorectal cancer screening market where recent colonoscopy guidelines have created opportunities for new, improved diagnostic technologies. SpectraScience is further evaluating the potential of its technology in an array of additional indications and using a combination of next-generation, light-based technologies.

* The Corporate Snapshot was last updated on August 5, 2015.

Slide Show